W W W . Q I A G E N . C O MSlide: 1

Dr. Joachim Schorr

Managing Director and SVP Global R&D

SG Cowen 6th Annual Global Health Care Conference

Barcelona, November 10, 2005

W W W . Q I A G E N . C O MSlide: 2

Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).

The following slides may contain certain summary information about QIAGEN N.V.’s operating income, net income, and earnings per share, which information is presented on a “non-GAAP financial measures”basis rather than in accordance with U.S. generally accepted accounting principles (“GAAP”). Please review QIAGEN’s recent press releases for information on the company’s operating income, net income, and earnings per share for specific periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the company’s reports on Form 20-F and 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission and which are available on QIAGEN’s homepage under www.QIAGEN.com.

Forward Looking Statements Intro

W W W . Q I A G E N . C O MSlide: 3

As the innovative market and technology leader, QIAGEN creates indispensable solutions that set standards in enabling access to content from any biological sample.

Our mission is to enable our customers to achieve outstanding success and breakthroughs in research, applied markets, drug development and molecular diagnostics. We thereby make improvements in life possible.

Our commitment to the markets we serve drives our innovation and leadership in all areas where solutions such as sample collection, stabilization, separation, purification, storage, handling and processing are required.

The exceptional talent, skill and passion of our employees are key to QIAGEN’s excellence, success and value.

We create indispensable solutions that enable access to content from any biological sample Intro

W W W . Q I A G E N . C O MSlide: 4

Revenues: 2004: $ 380.6 million 96–04 CAGR: 27%1

Net income: 2004: $ 57.32million 96–04 CAGR: 35%2

EPS: 2004: $ 0.392 96–04 CAGR: 33%2

Product Range:

Approx. 320 consumable products to separate and purify nucleic acids and proteinsInstrumentation for certain applicationsMolecular diagnostics and research test kits

IP: 315 issued patents, 263 pending patentsOver 500 patents under license

Customers: >400,000 customers in Academia,Industrial (Pharma/Biotech), and Diagnostics

Employees: 1.527 people based in 15 subsidiaries

1 excluding synthetic DNA business unit sold in Q2 20042 excluding acquisition, restructuring and related charges as well as amortization on acquired IP

QIAGEN at a Glance Intro

W W W . Q I A G E N . C O MSlide: 5

Technology Leadership Sales Strength

CUSTOMER

Research

Pharma KAM

Clinical

MDX

Inside Sales

E-commerce

Forensic

QIAGEN: Standards which Enable Access to the Content of Any Biological Sample

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

Financials

Intro

W W W . Q I A G E N . C O MSlide: 6

Sales Strength

CUSTOMER

Research

Pharma KAM

Clinical

MDX

Inside Sales

E-commerce

Forensic

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

Financials

QIAGEN: Standards which Enable Access to the Content of Any Biological Sample

Technology Leadership

Technology Leadership

W W W . Q I A G E N . C O MSlide: 7

Blood - a Complex Biological Sample

Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, ...

Technology Leadership

W W W . Q I A G E N . C O MSlide: 8

Blood - a Complex Biological SampleNucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, DNA, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmaticreticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, …

Technology Leadership

W W W . Q I A G E N . C O MSlide: 9

Nucleic acids are of significant interestNucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, DNA, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmaticreticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, …

Technology Leadership

W W W . Q I A G E N . C O MSlide: 10

QIAGEN Preanalytical Technologies for Best Results Technology

Leadership

DNA

W W W . Q I A G E N . C O MSlide: 11

Bio

logi

cal

sam

ples

Nucleic Acids/Genetic Target

Assays/Application

Bacteria

Tissue

BloodgD

NA

SequencingSNP-Genotyping

Microarrays

RN

A

pDN

A

Pro

tein

s

vNA

Co-

purif

.

Oth

ers

Expression Profiling

Plants

Animal

Viruses

Others (Cloning, PCR...)

QIAGEN Product Dimensions Technology Leadership

W W W . Q I A G E N . C O MSlide: 12

QIAGEN’s Leadership in Pre-analytical Tools Technology Leadership

Unparalleled range of applications

Standardizes processes

Time savings

Highest purity

Automation

Up-scaling

Non- toxic reagents used

Highest convenience

Ease of use

Compatible with down-stream applications

Easiest integration into already existing platforms

Mar

ket s

hare

100%

Home Brew

Competitors

W W W . Q I A G E N . C O MSlide: 13

QIAGEN has Significant Marketing and Sales Power

Technology Leadership

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

Financials

Sales Strength

CUSTOMER

Research

Pharma KAM

Clinical

MDX

Inside Sales

E-commerce

Forensic

Sales strength

W W W . Q I A G E N . C O MSlide: 14

Strong Sales and Marketing Force

Americas < 50% of Sales: Sales and Marketing Force: 210Mid-teens growth in 05

Europe Approx 40% of SalesSales and Marketing Force: 270Low-teens growth in 05Mixed, some much faster

Asia Approx 10% of SalesSales and Marketing Force: 50Low-teens growth in 05

530 sales and marketing professionals – on one clear and focused mission

MARKETS

Research

Pharma KAM

Clinical

MDX

Inside Sales

E-commerce

Forensic

SPECIALISTS

Channels

Sales strength

W W W . Q I A G E N . C O MSlide: 15

Third Quarter 2005 Revenue Distribution

Consumables15% growthQ1-Q4 launch campaigns withstrong performance

Instruments-14% growth yoystrong growth in major BioRobotproduct linesOEM still delayed

10%

Japan8% of salesFlat, outlook improving

RoW2% of sales

North America48% of sales

8% growth

Europe 42% of sales13% growth

89%

Other (1%)Focusing companyReducing servicebusiness (e.g. contract manufacturing)

W W W . Q I A G E N . C O MSlide: 16

QIAGEN‘s Brand Equity

Standard & Poor's - Report July 16th, 2004

“In less than two decades, QIAGEN has become the world's leading provider of "enabling technologies for the separation purification and handling of nucleic acids" - addressing applications in four key markets: research, gene therapy, molecular diagnostics and genomics & drug discovery. Key to the success of the company is the brand image as well as the strong technological investment“

Frost & Sullivan - Innovation Award 2003

A comprehensive end-user study conducted by Frost & Sullivan entitled “U.S. Nucleic Acid Isolation Markets” identified QIAGEN as the market-leading provider of innovative and cost-effective products for the purification of nucleic acids. In an analysis entitled The World Robotics in Biology: Liquid Handling Markets, Frost & Sullivan identified QIAGEN as the undisputed leader in product innovation in this area and highlighted QIAGEN for product innovation in various automation solutions targeting molecular diagnostics and research.

Sales strength

W W W . Q I A G E N . C O MSlide: 17

Technology Leadership Sales Strength

CUSTOMER

Research

Pharma KAM

Clinical

MDX

Inside Sales

E-commerce

Forensic

Financials

QIAGEN is Addressing Key Growth Markets Growth Drivers

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

W W W . Q I A G E N . C O M

Standardization& Integration

Standardization& Integration

SystemsBiology

SystemsBiologyDisseminationDissemination

3

1

Discovery Clinical phases

Plasmid

Cells

2

gDNA

RNA

Executing on our MissionCatalytic Acquisitions

Molecular Diagnostics

Applied Markets

Academic research

BiomedicalResearch

Pharma

Personalized Medicine

Proteins

Routine use

- Separate Diagnostics sales force - Separate Applied Testing sales focus

- Forensics- Veterinary- Manufacturing/PAT

- Pharmacogenomics sales initiative- Personalized Medicine Coalition

- QProteome – protein fractionation- Haplotype specific extraction- Epigenomics alliance

- Alliances in DX- Roche, J&J, Beckman etc.

-510ks, CE-markings

Growth Drivers

W W W . Q I A G E N . C O MSlide: 19

Molecular Diagnostics

Executing on strategy during 2005:

Expanding portfolio with diagnostic assays (artus, PG Biotech)

Standards in sample preparation – linking with tests (assays)

CE and FDA regulated products

Numerous strategic alliances

Impressive pipeline with >12 new assays to come in next 4 months

QIAGEN’s Core Activities in MDx:

Direct selling (80% of MDx revenues) we control

OEM products (15% of MDx revenues) less predictable(QIAGEN products shipped to partners)

OEM development (5% of MDx revenues) less predictable(development of solutions for partners)

IVD - facilitate diagnosis – influence therapy decisions

W W W . Q I A G E N . C O MSlide: 20

Total Diagnostics Markets

Diagnostics is changing – we are in the right position.

Diabetes Care21%

ClinicalChemistry

14% Near PatientTesting

11%

Immunochemistry25%

Other IVD23%

Molecular Diagnostics6%,

$ 2 billion market

Source: company estimates for 2006, various industry research reports

W W W . Q I A G E N . C O MSlide: 21

QIAGEN Molecular Diagnostics MarketsSubsegments

Estimated market volume: > US$ 2 billion (2006)Estimated no. of tests per year: > 65 millionEstimated market growth: > 15%

Pathogen testing is growing into a multi billion US$ market

Viral Infections39%

Non-Viral Infections12%

Genetic Testing13%

Oncology11%

Blood banksOthers25%

Source: company estimates, various industry research reports

W W W . Q I A G E N . C O MSlide: 22

QIAGEN Molecular Testing MarketsApplied Testing Markets

Applied testing markets provide > US$5 bill. by 2008Vast opportunities with conversion to molecular testing

Estimated molecular market volume: > US$ 500 million (2008)Estimated no. of tests per year: > 25 million (2008)Estimated market growth: > 20%

QC Pharma

Biosecurity

Veterinary

Food Pathogens

Pharmacogenomics

Food GMO

Human ID

Source: company estimates, various industry research reports

W W W . Q I A G E N . C O MSlide: 23

QIAGEN and Avian FluComplete Technology Portfolio

1) Screening (animals, food)

PG Biotech: Avian influenza Virus FQ-PCR Detection Kit,first and only PCR based, SFDA approved avian flu test worldwide (launched 2004)

QIAGEN (prev. artus): artus™ Influenza LC RT-PCR Kitfor influenza A/B, also detects H5N1

2) IVD

QIAGEN (prev. artus): artus™ Influenza/H5 LC RT-PCR Kit, a specific, sensitive and fast nucleic acids (RNA) test of the avian flu (H5N1) virus in humans

3) QIAGEN components standard in homebrew test solutions

E.g.: WHO/CDS/CSR/NCS/2005 – WHO Animal Influenza Manual www.who.int/csr/resources/publications/influenza/whocdscsrncs20025rev.pdf

E.g.: WHO-Recommended laboratory tests to identify avianinfluenza A virus in specimens from humans

www.who.int/csr/disease/avian_influenza/guidelines/avian_labtests2.pdf

QIAGEN – speed and innovation in molecular diagnosticsLeading supplier in avian flu testing

W W W . Q I A G E N . C O MSlide: 24

QIAGEN and Avian FluH5N1 Test

1) Direct detection:

2) Two layer detection

Speed and innovation in molecular diagnostics

- Highly sensitive

- Captures moremutations

- Broad screening, yet specific

- Fast

- Economical

- Needs stableregions in targetnucleic acid

W W W . Q I A G E N . C O MSlide: 25

Chinese Biotech Market Today

Life science grants to reach US$ 2.6 bn/year

Commercialization and R&D encouraged by government

Two main segments:

Biomedical- world‘s largest pharmaceutical market by 2020- Biotech to be a key driver- Focus on Dx, pharmacogenomics

Agricultural Biotech:- Building largest Ag-biotech capacity outside

North America

Today: largest biology student population;One of three scientific publications with Chinese co-authors

Chinese biotech still small – but exciting growth opportunities

W W W . Q I A G E N . C O MSlide: 26

QIAGEN Activities in China

QIAGEN

Established focused, local marketing presence and office in Shanghai

Strengthened distribution channels

Local Brand: Acquisition of TianWei Times in Beijing provided network and operational base to address specific local sample preparation needs of research community

Diagnostics

PG Biotech leading MDx company, gaining share

Substantial sales channel

Development and manufacturing

Regulatory base

Expanding in – and – from China!

W W W . Q I A G E N . C O MSlide: 27

QIAGEN‘s Leadership

strong leadership in nucleic acidsexpanding leadership in proteinscomplete portfolio for all markets and segments

leadership in research markets with PCR and other bioassay technologies

5th largest molecular diagnostics company –a leader in PCR assays

Growth Drivers

W W W . Q I A G E N . C O MSlide: 28

Technology Leadership Sales Strength

CUSTOMER

Research

Pharma KAM

Clinical

MDX

Inside Sales

E-commerce

Forensic

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

QIAGEN Strong Financial Base – Exciting Model Financials

Financials

W W W . Q I A G E N . C O MSlide: 29

QIAGEN Third Quarter 2005 at a Glance

Exceeded

In line

1 excluding acquisition, restructuring, integration and related charges2 excluding acquisition, restructuring, integration and related charges as well as

amortization on acquired IP3 computed using cash from operations divided by number of fully diluted shares

Soft OEM instrumentation business and contract research business generates lower revenue,US$2mill. revenue shortfall

Exceeded operating income margin

In line with EPS guidanceWell on track to make FY guidance of US$ 0.44 – 0.47

Soft due to OEMIn US$ millions unless indicated Guidance

Guidance CERFebruary 2005 Achieved Growth

Net sales 105-107 101.8 98.7 13%

Operating income1 24-26% 27% 10%

EPS (US$)1 0.11-0.13 0.12 20%

Adjusted EPS (US$)2 0.12Cash EPS3 0.13

W W W . Q I A G E N . C O MSlide: 30

QIAGEN Third Quarter 2005 Revenue Growth

Consumables: Sustainable growth rate of 15%

Instruments: QIAGEN BioRobots solid 9% growth YTD

OEM weak due to delayed product launches ofsome of our partners in molecular diagnostics

Others: Focusing the companyReducing revenues(mainly services and OEM contract research)Exercising strategy to grow

Q3 2005

Consumables 15%Instruments -14%Others -56%

Total 9%

W W W . Q I A G E N . C O MSlide: 31

Operating margin: Exceeded guidance

Managed S&M and G&A costs

Focus on high gross margin consumables

Good base going forward

66%

27%

16%

70%

28%

19%

Gross margin Operating incomemargin*

Net income margin*

Q3 2004

Q3 2005

* excluding acquisition, restructuring, integration and related charges as well as amortization onacquired IP

QIAGEN Margin Development - the Driver for Profitability

W W W . Q I A G E N . C O M

Already achieved in Q3 2005

Adjusted Guidance

No impact on EPS!!

- 32 -

* based on foreign exchange rates used for guidance communicated on February 15, 2005

1 excluding acquisition, restructuring, integration and related charges

9M 2005CER to

guidance*Guidance

Nov 8, 2005

Revenues (in mio US$) 294,1 298,7 405 - 407

Operating margin1 25% 25% 25% - 26%

EPS (US$)1 US$ 0.32 US$ 0.32 US$ 0.44 - 0-47

*

W W W . Q I A G E N . C O MSlide: 33

US/Can Europe Asia RoWTotal

Q3 05Total

Q2 05 Growth

Production 76 267 21 364 354 3%R&D 18 282 3 303 305 -1%Sales 218 249 56 15 538 519 4%Marketing 24 71 24 1 120 113 6%Admin 50 143 9 4 206 204 1%

Total 386 1012 113 20 1531 1495 2%

Employees September 30, 2005

Further strengthened

Sales & Marketing

W W W . Q I A G E N . C O MSlide: 34

Positive Outlook on 2005

Solid third quarter – strong growth in core business

Good financial performance

Operating margin already achieved FY guidanceFurther improvement possible

Cash > $210 million

EPS first nine months 2005 achieved $0.32 (excl.)Well on track to achieve FY guidance

Strong strategic momentum

Positioning QIAGEN as a leading Dx company

Expanding market leadership in Asia

Three accretive acquisitions in Q3 2005

Exciting new product launches

Leveraging operational strength to further improve margins

Successful integrations of acquired businesses

Executing on Plans – Expanding – Setting Standards